Transgene raises funds with the Talisman project

Transgene SA, a French biopharmaceutical company, has announced a share issue as part of the Talisman project. This project involves a capital increase through public and private offerings. The expected gross amount is approximately €105 million, including an offering to individual investors via the PrimaryBid platform.

The main objective is to finance the acceleration of the myvac® program, developed in the field of cancer. Planned over several years, the funds are intended to cover phase 2 of the clinical trial and the launch of a new phase 1 trial.

The issuance will be carried out on Euronext Paris at a price not exceeding €1.36 per share. Transgene emphasizes that trading in its shares will be temporarily suspended to ensure a smooth transition of the transaction.